Showing 3291-3300 of 5661 results for "".
- First Patient Dosed in TrialSpark's Phase 2 Trial of ASN008-201 in ADhttps://practicaldermatology.com/news/first-patient-dosed-in-trailsparks-phase-2-trial-of-asn008-201-in-ad/2461736/The first patient has been dosed in TrialSpark’s Phase 2 clinical trial for ASN008-201, a topical sodium channel blocker in development for pruritus associated with atopic dermatitis (AD). This clinical trial is a randomized, double-blind, vehicle-controlled, Phase 2 tr
- Game On: Top Derm Video Game Boosts Clinical Decision Making Among Seasoned Doctorshttps://practicaldermatology.com/news/game-on-top-derm-video-game-boosts-clinical-decision-making-among-seasoned-doctors/2461534/Medical video games increase the competence and clinical decision-making of practicing physicians, a new study by Level Ex shows. Substantial research has demonstrated video-game-based medical training’s effectiveness in the short-term. These studies primarily focused on medi
- Phase 2 Data: Jeuveau “Extra-Strength” Dose Produces Lasting Resultshttps://practicaldermatology.com/news/phase-2-data-jeuveau-extra-strength-dose-produces-lasting-results/2461528/Evolus' Jeuveau Extra-Strength achieved one-point improvement on the Glabellar Lines Scale with the duration of effect lasting 26 weeks, representing a prolonged 6-month performance, the Company reports. The extra-strength glabellar line study is a multicenter, double
- Topline Results: Union's Oral Orismilast Improves PASI by Week 16 in Patients with Moderate to Severe PsOhttps://practicaldermatology.com/news/topline-results-unions-oral-orismilast-improves-pasi-by-week-16-in-patients-with-moderate-to-severe-pso/2461489/Oral orismilast performed well in adult patients with moderate to severe psoriasis, according to topline results from the IASOS Phase 2b study. Data from the 202 patients randomized and dosed in the study showed that all active arms of oral orismilast achieved the primary endp
- Coming Soon? The first FDA-approved Topical Prescription Product for Molluscumhttps://practicaldermatology.com/news/coming-soon-the-first-fda-approved-topical-prescription-product-for-molluscum/2461485/Ligand Pharmaceuticals Inc.’s partner Novan submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for berdazimer gel, 10.3% (SB206) for the topical treatment of molluscum contagiosum. Assuming the filing is accepted b
- Kintor Pharma Completes Enrollment and Dosing in Phase I Clinical Trial of AGA, Acne Drughttps://practicaldermatology.com/news/kintor-pharma-completes-enrollment-and-dosing-in-phase-i-clinical-trial-of-aga-acne-drug/2461404/Kintor Pharmaceutical Limited has completed the enrollment and dosing of 120 subjects for its U.S. phase I clinical trial of GT20029 for the treatment of androgenetic alopecia (AGA) and acne. Developed through Kintor Pharma's proprietary Proteolysis Targeting Chimera (PROTAC) platfo
- First Patient Dosed in Phase 1b/2 Trial of Dermaliq Therapeutics's DLQ02 for PsOhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-1b2-trial-of-dermaliq-therapeuticss-dlq02-for-pso/2461310/The first patient has been dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor, Dermaliq Therapeutics, Inc. reports. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaqu
- Rodan + Fields Gives Back: Company Announces More Donations from Youth Empowerment Fundhttps://practicaldermatology.com/news/rodan-fields-gives-back-company-announces-more-donations-from-youth-empowerment-fund/2461300/Rodan + Fields has announced the second round of donations from the Youth Empowerment Fund through their support of the Prescription for Change project. Launched in August 2021, the Fund will invest a total of $5 Million over three years to empower young people to l
- Aesthetics Biomedical Inc. Receives Third U.S. Patent for “Biological Preserving Composition and Methods of Use” for SoME Skincare Product Linehttps://practicaldermatology.com/news/aesthetics-biomedical-inc-receives-third-us-patent-for-biological-preserving-composition-and-methods-of-use-for-its-some-skincare-product-line/2461296/Aesthetics Biomedical Inc. scored its third U.S. patent for “biological preserving composition and methods of use” for its SoME skincare product line. The patent covers topical compositions for combining biologics with skincare preserving the exclusivity of SoME Skincar
- CeraVe, Top Derms, and Skincare Enthusiasts Partner to Teach Consumers to #CleanseLikeaDermhttps://practicaldermatology.com/news/cerave-top-derms-and-skincare-enthusiasts-partner-to-teach-consumers-to-cleanselikeaderm/2461283/CeraVe is teaming up with board-certified dermatologists and two of the biggest dermatologist influencers on social media today – Dr. Dustin Portela (@208skindoc) and Dr. Michelle Henry (@drmichellehenry) – to host a global livestreamed event with skincare enthusiast and content creat